Autor: |
Faisal Raza, Juan Ren, Jun Yan, Hajra Zafar, Haopeng Wan, Xue Chen, Qingrong Cui, Haiyang Li, Xiangqi Wang |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Recent Patents on Anti-Cancer Drug Discovery. 18 |
ISSN: |
1574-8928 |
DOI: |
10.2174/1574892818666230417093208 |
Popis: |
Background: As a pentacyclic triterpenoid, OA (oleanolic acid) has exhibited anti-inflammatory, immunomodulatory and antitumor effects. VEGFR-2 (vascular endothelial cells receptor-2) tyrosine kinase activity could be inhibited by apatinib, a small-molecule anti-angiogenic agent. Thus, this study sought to investigate the mechanism underlying the synergistic anti-tumor activity of combined OA and apatinib. Materials and Methods: Through CCK8 (Cell counting kit 8 assay), flow cytometric and western blotting techniques, we conducted in vitro studies on apatinib and OA effects on cell proliferation and apoptosis in H22 cell line. H22 tumor-burdened mice model was established in vivo, while the related signaling pathways were studied via pathological examination, western blotting and qPCR (quantitative polymerase chain reaction). Results: Growth of H22 cells in vitro and in vivo could be inhibited effectively by apatinib and OA. Thus, OA repaired liver function and inhibited oxidative stress induced by apatinib. Conclusion: OA can treat apatinib induced liver injury in H22 Tumor-burdened mice by enhancing the suppresssive effect of apatinib on the growth of tumor. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|